AbbVie to Buy Cerevel Therapeutics for $8.7 Billion
Wall Street Journal
AbbVie will acquire neuroscience-drug maker Cerevel Therapeutics Holdings for $45 a share, giving the company an equity value of about $8.7 billion.
https://www.wsj.com/articles/abbvie-to-buy-cerevel-therapeutics-for-8-7-billion-c4ca7d85